PRR11 and breast carcinoma: In the PRISM repurposing 19Q3 dataset30, PRR11-amplified ER+ breast cancer cell lines displayed a lower sensitivity to the ER antagonist fulvestrant compared to cells without PRR11 amplification (Fig. 3g).